Methods and compositions for the prevention and treatment of influenza
This disclosure relates to the prevention and treatment of Influenza, and more particularly Influenza A Virus Subtype H1N1, with the use of a pharmaceutical composition comprising one or more digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes. The disclosure further relates to the use of an individual's fecal chymotrypsin level as an indicator, e.g., biomarker of whether an individual may be more susceptible to Influenza, e.g., Influenza A Subtype H1N1, and/or whether an individual will benefit from administration of the described pharmaceutical compositions. Use of the compositions as sanitizers, antiseptics, disinfectants, and detergents, e.g., to reduce or eradicate influenza virus present on living or inanimate surfaces is also contemplated.
1. A method for the treatment of an Influenza virus in a mammal or a bird, comprising orally administering to the mammal or bird a therapeutically effective amount of a coated pharmaceutical composition containing a sole bioactive substance that consists of digestive enzymes; wherein the digestive enzymes comprise a combination of at least one lipase and at least one protease; and wherein the Influenza virus is treated.
2. The method of claim 1 , wherein the Influenza virus comprises an Influenza Type A virus, an Influenza Type B virus, an Influenza Type C virus, a Subtype H1N1 virus, or a Subtype H5N1 virus.
3. The method of claim 1 , wherein the digestive enzymes further comprise at least one amylase.
4. The method of claim 3 , wherein the coated pharmaceutical composition comprises at least one amylase, at least one protease comprising chymotrypsin and trypsin, and at least one lipase.
5. The method of claim 3 , wherein the digestive enzymes are provided as pancreatin.
6. The method of claim 3 , wherein the at least one amylase is present in the coated pharmaceutical composition in an amount of from about 10,000 to about 60,000 U.S.P. units per dose.
7. The method of claim 1 , wherein the digestive enzymes are pancreatic enzymes.
8. The method of claim 1 , wherein the digestive enzymes comprise avian enzymes or pig enzymes.
9. The method of claim 1 , wherein the at least one protease comprises chymotrypsin and trypsin.
10. The method of claim 9 , wherein the chymotrypsin is present in the coated pharmaceutical composition in an amount of from about 2 to about 5 mg per dose, and wherein the trypsin is present in the coated pharmaceutical composition in an amount of from about 60 to about 100 mg per dose.
11. The method of claim 1 , wherein the digestive enzymes are animal enzymes, microbial enzymes, plant enzymes, or are synthetic enzymes.
12. The method of claim 11 , where the digestive enzymes are animal enzymes from a pig pancreas.
13. The method of claim 1 , wherein the mammal is a pig, a horse, a cow, a dog, a cat, a monkey, a rat, a mouse, a sheep, a goat, or a human.
14. The method of claim 1 , further comprising vaccinating the mammal or bird with a trivalent inactivated influenza vaccine (TIV) or a live, attenuated influenza vaccine (LAIV); treating the mammal or bird with an anti-viral medication; or both.
15. The method of claim 1 , wherein the at least one protease and the at least one lipase in the pharmaceutical composition in United States Pharmacopoeia (U.S.P.) units are present in a ratio of protease to lipase of from about 1:1 to about 20:1.
16. The method of claim 1 , wherein the at least one protease and the at least one lipase in the pharmaceutical composition in U.S.P. units are present in a ratio of protease to lipase of from about 4:1 to about 10:1.
17. The method of claim 1 , wherein the coated pharmaceutical composition further comprises one or more enzymes selected from the group consisting of a cellulase, a sucrase, a maltase, and a hydrolase.
18. The method of claim 1 , wherein the at least one protease is present in the coated pharmaceutical composition in an amount of from about 10,000 to about 70,000 U.S.P. units per dose.
19. The method of claim 1 , wherein the at least one lipase is present in the coated pharmaceutical composition in an amount of from about 4,000 to about 30,000 U.S.P. units per dose.
20. The method of claim 1 , wherein the at least one protease and the at least one lipase are present in the coated pharmaceutical composition in U.S.P. units in a ratio of protease to lipase of 4:1, 7:1, 10:1, or 12:1.
21. The method of claim 1 , wherein the digestive enzymes are coated with a lipid or a lipid blend.
22. The method of claim 1 , comprising administering at least two doses of the coated pharmaceutical composition to the mammal or bird.
23. The method of claim 1 , comprising treating the mammal, wherein the mammal comprises a child under the age of 2.
24. A method for the treatment of an Influenza virus in a mammal having a subnormal level of fecal chymotrypsin (FCT), comprising orally administering to the mammal a therapeutically effective amount of a coated pharmaceutical composition containing a sole bioactive substance that consists of digestive enzymes; wherein the digestive enzymes comprise a combination of at least one lipase and at least one protease, and wherein the Influenza virus is treated.
25. The method of claim 24 , wherein the digestive enzymes further comprise at least one amylase.
26. The method of claim 24 , wherein the digestive enzymes are coated with a lipid or a lipid blend.
27. The method of claim 24 , wherein the Influenza virus comprises an Influenza Type A virus, an Influenza Type B virus, an Influenza Type C virus, a Subtype H1N1 virus, or a Subtype H5N1 virus.